No Association of Matrix Metalloproteinase [MMP]-2 (−735C > T) and Tissue Inhibitor of Metalloproteinase [TIMP]-2 (−418G > C) Gene Polymorphisms with Cervical Cancer Susceptibility

[1]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[2]  R. Zhou,et al.  Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China , 2009, Molecular Biology Reports.

[3]  Bin Wang,et al.  Tissue inhibitor of metalloproteinase-2 G-418C polymorphism is associated with an increased risk of gastric cancer in a Chinese population. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  A. Halpern,et al.  Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression , 2007, Journal of Negative Results in BioMedicine.

[5]  I. Delgado-Enciso,et al.  Matrix Metalloproteinase-2 Promoter Polymorphism Is Associated with Breast Cancer in a Mexican Population , 2007, Gynecologic and Obstetric Investigation.

[6]  E. Nkenke,et al.  Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. , 2007, Oncology reports.

[7]  P. O-Charoenrat,et al.  The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. , 2006, Oral oncology.

[8]  W. Tan,et al.  Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. , 2003, Carcinogenesis.

[9]  I. König,et al.  Tissue Inhibitor of Metalloproteinases-1, −2, and −3 Polymorphisms in a White Population With Intracranial Aneurysms , 2003, Stroke.

[10]  C. Sheehan,et al.  Prognostic Significance of Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 Expression in Prostate Cancer , 2003, Modern Pathology.

[11]  J. Vítovec,et al.  Two MMP-2 Promoter Polymorphisms (–790T/G and –735C/T) in Chronic Heart Failure , 2003, Clinical chemistry and laboratory medicine.

[12]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[13]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[14]  K. Sekizawa,et al.  Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. , 2001, The European respiratory journal.

[15]  L. Devy,et al.  Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. , 2001, Cancer research.

[16]  I. Stamenkovic.  Matrix metalloproteinases in tumor invasion and metastasis. , 2000, Seminars in cancer biology.

[17]  P. Soloway,et al.  TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo * , 2000, The Journal of Biological Chemistry.

[18]  D M Parkin,et al.  International trends in incidence of cervical cancer: II. Squamous‐cell carcinoma , 2000, International journal of cancer.

[19]  R. E. Luna,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. , 2000, Human pathology.

[20]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[21]  R. Marks,et al.  Squamous cell carcinoma , 1996, The Lancet.

[22]  G. Rousseau,et al.  Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Gene.

[23]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.